156 related articles for article (PubMed ID: 22266893)
1. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.
Gagne JJ; Rassen JA; Walker AM; Glynn RJ; Schneeweiss S
Epidemiology; 2012 Mar; 23(2):238-46. PubMed ID: 22266893
[TBL] [Abstract][Full Text] [Related]
2. An event-based approach for comparing the performance of methods for prospective medical product monitoring.
Gagne JJ; Walker AM; Glynn RJ; Rassen JA; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):631-9. PubMed ID: 22223544
[TBL] [Abstract][Full Text] [Related]
3. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
[TBL] [Abstract][Full Text] [Related]
4. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment.
Gagne JJ; Wang SV; Rassen JA; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):619-27. PubMed ID: 24788694
[TBL] [Abstract][Full Text] [Related]
5. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
[TBL] [Abstract][Full Text] [Related]
6. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system.
Gagne JJ; Glynn RJ; Rassen JA; Walker AM; Daniel GW; Sridhar G; Schneeweiss S
Clin Pharmacol Ther; 2012 Jul; 92(1):80-6. PubMed ID: 22588606
[TBL] [Abstract][Full Text] [Related]
7. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
Psaty BM; Furberg CD; Ray WA; Weiss NS
JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
[TBL] [Abstract][Full Text] [Related]
8. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
[TBL] [Abstract][Full Text] [Related]
9. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
[TBL] [Abstract][Full Text] [Related]
10. A novel algorithm for detection of adverse drug reaction signals using a hospital electronic medical record database.
Park MY; Yoon D; Lee K; Kang SY; Park I; Lee SH; Kim W; Kam HJ; Lee YH; Kim JH; Park RW
Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):598-607. PubMed ID: 21472818
[TBL] [Abstract][Full Text] [Related]
11. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
Szarfman A; Machado SG; O'Neill RT
Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
[TBL] [Abstract][Full Text] [Related]
12. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
[TBL] [Abstract][Full Text] [Related]
13. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.
Ryan PB; Madigan D; Stang PE; Overhage JM; Racoosin JA; Hartzema AG
Stat Med; 2012 Dec; 31(30):4401-15. PubMed ID: 23015364
[TBL] [Abstract][Full Text] [Related]
14. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
Hauben M; Vegni F; Reich L; Younus M
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
[TBL] [Abstract][Full Text] [Related]
15. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
[TBL] [Abstract][Full Text] [Related]
16. Detecting adverse drug reactions in discharge summaries of electronic medical records using Readpeer.
Tang Y; Yang J; Ang PS; Dorajoo SR; Foo B; Soh S; Tan SH; Tham MY; Ye Q; Shek L; Sung C; Tung A
Int J Med Inform; 2019 Aug; 128():62-70. PubMed ID: 31160013
[TBL] [Abstract][Full Text] [Related]
17. Baycol withdrawn from market.
SoRelle R
Circulation; 2001 Aug; 104(8):E9015-6. PubMed ID: 11521677
[No Abstract] [Full Text] [Related]
18. A primer of drug safety surveillance: an industry perspective. Part III: Managing adverse-event data.
Allan MC
J Pharm Technol; 1992; 8(6):259-73. PubMed ID: 10122649
[TBL] [Abstract][Full Text] [Related]
19. A pharmacoepidemiological network model for drug safety surveillance: statins and rhabdomyolysis.
Reis BY; Olson KL; Tian L; Bohn RL; Brownstein JS; Park PJ; Cziraky MJ; Wilson MD; Mandl KD
Drug Saf; 2012 May; 35(5):395-406. PubMed ID: 22506565
[TBL] [Abstract][Full Text] [Related]
20. Do delays in data availability limit the implementation of near real-time vaccine safety surveillance using the Clinical Practice Research Datalink?
Leite A; Thomas SL; Andrews NJ
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):25-29. PubMed ID: 29193554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
